“Rheum” for Improvement: Review of Rheumatoid Arthritis Treatment Guidelines

<p>Chelsea M. Morken, PharmD (<a href='https://twitter.com/ChelseaMorken'>@ChelseaMorken</a>) explains the pathophysiology of rheumatoid arthritis (RA), describes the literature regarding cardiovascular risks with Janus-kinase inhibitors and recognizes appropriate initial therapy based on patient specific factors.</p> <p>For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs <a href='https://twitter.com/MayoPharmRes'>@MayoPharmRes</a> or the host, Garrett E. Schramm, Pharm.D., <a href='https://twitter.com/garrett_schramm'>@garrett_schramm</a> on Twitter!</p> <p>You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at <a href='https://ce.mayo.edu/'>https://ce.mayo.edu/</a> or on Twitter <a href='https://twitter.com/MayoMedEd'>@MayoMedEd</a>. </p>